Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin with R-CHP in CD30+ B-Cell Lymphomas
NCT01994850Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Nov 2013
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in primary mediastinal large B-cell lymphoma (PMBCL), diffuse large B-cell lymphoma (DLBCL), gray zone lymphoma (GZL), sponsored by Abramson Cancer Center. Started Nov 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)diffuse large B-cell lymphoma (DLBCL)gray zone lymphoma (GZL)
Beyond the preview
Go deeper on NCT01994850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994850.